FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2296362429> ?p ?o ?g. }

• W2296362429 endingPage "418" @default.
• W2296362429 startingPage "416" @default.
• W2296362429 abstract "Combination antiretroviral therapy (cART) has significantly improved the clinical outcome for HIV-infected patients. Although the treatment is highly effective in driving the viremia to an undetectable level, it does not represent a cure, because a long-lived reservoir of latent virus remains. Persistent proviruses persist in latently infected resting memory CD4+ T cells and are found in many tissues, including blood, lymph nodes, central nervous system, and the gut. Eradication of the latent reservoir and the ability to truly cure an infected patient remain a significant challenge.1Crooks AM Bateson R Cope AB Dahl NP Griggs MK Kuruc JD et al.Precise quantitation of the latent HIV-1 reservoir: implications for eradication strategies.J Infect Dis. 2015; 212: 1361-1365Crossref PubMed Scopus (264) Google Scholar Many options have been explored to reverse latency, and a pharmacological approach is the current favorite. In this issue, Saayman et al.,2Saayman SM Lazar DC Scott TA Hart JR Takahashi M Burnett JC et al.Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex.Mol Ther. 2016; 24: 488-498Abstract Full Text Full Text PDF PubMed Scopus (94) Google Scholar Limsirichai et al.3Limsirichai P Gaj T Schaffer DV CRISPR-mediated activation of latent HIV-1 expression.Mol Ther. 2016; 24: 499-507Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar, and Ji et al.4Ji H Jiang Z Lu P Ma L Li C Pan H et al.Specific reactivation of latent HIV-1 by dCas9-SunTag-VP64-mediated guide RNA targeting the HIV-1 promoter.Mol Ther. 2016; 24: 508-521Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar each report their early explorations of a different approach: the use of a modified CRISPR/Cas9 system to reactivate latent HIV-1. These reports provide strong evidence that application of CRISPR/Cas9 can induce specific and effective reactivation of a latent HIV-1 promoter. The persistence of integrated provirus, despite aggressive therapy with antiretrovirals, represents a major barrier to truly curing HIV infection. The reservoir of latently infected cells is established early in infection within long-lived memory CD4+ T cells and persists throughout the life of the patient.5Chun TW Engel D Berrey MM Shea T Corey L Fauci AS et al.Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.Proc Natl Acad Sci USA. 1998; 95: 8869-8873Crossref PubMed Scopus (679) Google Scholar,6Karn J The molecular biology of HIV latency: breaking and restoring the Tat-dependent transcriptional circuit.Curr Opin HIV AIDS. 2011; 6: 4-11Crossref PubMed Scopus (140) Google Scholar,7Margolis DM Mechanisms of HIV latency: an emerging picture of complexity.Curr HIV/AIDS Rep. 2010; 7: 37-43Crossref PubMed Scopus (71) Google Scholar During this latent state, multiple factors associate with the viral long terminal repeat (LTR) and repress transcription.8Ruelas DS Greene WC An integrated overview of HIV-1 latency.Cell. 2013; 155: 519-529Abstract Full Text Full Text PDF PubMed Scopus (209) Google Scholar,9Donahue DA Wainberg MA Cellular and molecular mechanisms involved in the establishment of HIV-1 latency.Retrovirology. 2013; 10: 11Crossref PubMed Scopus (83) Google Scholar Among these factors are the histone deacetylases and other chromatin-modifying proteins that alter the chromatin structure of the integrated viral promoter to prevent access and binding by positive transcription factors.10Tyagi M Pearson RJ Karn J Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction.J Virol. 2010; 84: 6425-6437Crossref PubMed Scopus (205) Google Scholar These latently infected cells produce little to no viral proteins and thus escape easy identification as harboring the virus. Latently infected cells do not display any specific target for the immune system or antiviral drugs. Current attempts to reactivate latent HIV provirus involve the use of protein kinase C activators (i.e., prostratin and bryostatin) and histone deacetylase inhibitors (vorinostat and panobinostat).11Xing S Siliciano RF Targeting HIV latency: pharmacologic strategies toward eradication.Drug Discov Today. 2013; 18: 541-551Crossref PubMed Scopus (119) Google Scholar These agents have been shown to efficiently reactivate latent virus and have been proven safe. However, initial attempts to reduce the size of the latent reservoir using such reactivating agents have been unsuccessful.12Archin NM Bateson R Tripathy MK Crooks AM Yang KH Dahl NP et al.HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat.J Infect Dis. 2014; 210: 728-735Crossref PubMed Scopus (194) Google Scholar Therefore, a new strategy has been adopted, termed “shock and kill,” in which reactivation will be followed by a different treatment to kill the infected cell. Patients stay on cART to prevent the spread of infection to new cells. It is predicted that activation of virus will coincide with expression of markers that can be used to kill the infected cell either immunologically or through pharmaceutical intervention. Concerns remain and include the inability of clinically achievable levels of drug to reactivate all latent virus, increased susceptibility of T cells to infection following reactivating treatment, and suppression of cytotoxic T lymphocytes following treatment with nonspecific reactivating agents.13Jones RB O'Connor R Mueller S Foley M Szeto GL Karel D et al.Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes.PLoS Pathog. 2014; 10: e1004287Crossref PubMed Scopus (158) Google Scholar,14Lucera MB Tilton CA Mao H Dobrowolski C Tabler CO Haqqani AA et al.The histone deacetylase inhibitor vorinostat (SAHA) increases the susceptibility of uninfected CD4+ T cells to HIV by increasing the kinetics and efficiency of postentry viral events.J Virol. 2014; 88: 10803-10812Crossref PubMed Scopus (48) Google Scholar,15Cillo AR Sobolewski MD Bosch RJ Fyne E Piatak Jr, M Coffin JM et al.Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy.Proc Natl Acad Sci USA. 2014; 111: 7078-7083Crossref PubMed Scopus (175) Google Scholar Therefore, new approaches that can trigger HIV reactivation with high specificity and low toxicity are needed. The CRISPR/Cas9 system has been shown to be highly specific and may provide an avenue by which greater levels of activation can be achieved without detrimental off-target effects. Recent approaches to genetic engineering have created systems comprising diverse site-specific DNA-binding domains fused to various nucleases to allow relatively specific gene editing. The modular structure of two popular systems, transcription activator-like effector nucleases (TALENs) and zinc-finger nucleases (ZFNs), yields tools in which the nuclease domain can be deactivated and fused to a variety of alternative effector proteins (i.e., activators, repressors, transcription factors) to modify a specific locus, such as the promoter of the HIV provirus. However, the cost and complexity of protein engineering limits the potential of these systems. The recently developed CRISPR/Cas9 system provides a superior alternative to the existing protein-based approaches. The Cas9 protein is targeted to specific loci via co-delivery of an artificially designed single-guide RNA (sgRNA), making this a much more facile system to manipulate and exploit. The CRISPR/Cas9 system has previously been employed to disrupt the HIV-1 genome but not to reactivate latent virus.16Hu W Kaminski R Yang F Zhang Y Cosentino L Li F et al.RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection.Proc Natl Acad Sci USA. 2014; 111: 11461-11466Crossref PubMed Scopus (402) Google Scholar The three labs employed slightly different approaches in applying CRISPR/Cas9 technology to the reactivation of HIV-1. All of the groups made use of a nuclease-deficient Cas9, referred to as dCas9, which was coupled to different transactivating domains (Table 1 and Figure 1). There are multiple considerations when designing an sgRNA to guide Cas9: inclusion of a terminal protospacer adjacent motif (a short sequence of nucleic acids at the end of the sgRNA that is absolutely required for function) and the avoidance of off-target effects being the most critical. The authors of the studies designed very different sgRNAs that span the U3 (viral promoter) and R (transcription start site) regions of the viral LTR (Table 2). Common themes are found in the articles, such as the strong activation potential of sgRNAs that direct the modified dCas9 to regions in close proximity to nuclear factor-κB (NF-κB) transcription factor binding sites within the LTR. The utility of targeting a transactivating complex to this region (approximately 100 bases upstream of the transcription start site) has been previously demonstrated in other cellular promoters. Transcription of messenger RNA is a highly regulated process involving multiple factors that serve to recruit and activate the RNA Pol II complex. Production of messenger RNA requires that the correct factors are located at the right position at the right time. The observed hotspot at 100 bases upstream of transcription start reveals a general rule about activation of the Pol II complex and may be the reason why the virus has evolved sequence that recruits NF-κB to this specific location.Table 1Comparison of activation domains usedSaayman et at.2Saayman SM Lazar DC Scott TA Hart JR Takahashi M Burnett JC et al.Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex.Mol Ther. 2016; 24: 488-498Abstract Full Text Full Text PDF PubMed Scopus (94) Google ScholarLimsirichai et at.3Limsirichai P Gaj T Schaffer DV CRISPR-mediated activation of latent HIV-1 expression.Mol Ther. 2016; 24: 499-507Abstract Full Text Full Text PDF PubMed Scopus (76) Google ScholarJi et at.4Ji H Jiang Z Lu P Ma L Li C Pan H et al.Specific reactivation of latent HIV-1 by dCas9-SunTag-VP64-mediated guide RNA targeting the HIV-1 promoter.Mol Ther. 2016; 24: 508-521Abstract Full Text Full Text PDF PubMed Scopus (60) Google ScholardCas9-VP64+++dCas9-VPR+dCas9-VPR + sgSAM+dCas9-VP64 + sgSAM+dCas9-p300+dCas9-SunTag+dCas9, deactivated or “dead” Cas9; sgSAM, single-guide synergistic activation mediator. Open table in a new tab Table 2Summary of effectiveness in targeting various regions of HIV-1 for activationRegionSaayman et at.2Saayman SM Lazar DC Scott TA Hart JR Takahashi M Burnett JC et al.Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex.Mol Ther. 2016; 24: 488-498Abstract Full Text Full Text PDF PubMed Scopus (94) Google ScholardCas9-VP64Limsirichai et at.3Limsirichai P Gaj T Schaffer DV CRISPR-mediated activation of latent HIV-1 expression.Mol Ther. 2016; 24: 499-507Abstract Full Text Full Text PDF PubMed Scopus (76) Google ScholardCas9-VP64 + sgSAMJi et at.4Ji H Jiang Z Lu P Ma L Li C Pan H et al.Specific reactivation of latent HIV-1 by dCas9-SunTag-VP64-mediated guide RNA targeting the HIV-1 promoter.Mol Ther. 2016; 24: 508-521Abstract Full Text Full Text PDF PubMed Scopus (60) Google ScholardCas9-SunTagModulatory+++ +Enhancer+ ++++Core−+−Rn/a+−U5n/a+−dCas9, deactivated or “dead” Cas9; n/a, not applicable; sgSAM, single-guide synergistic activation mediator. Open table in a new tab dCas9, deactivated or “dead” Cas9; sgSAM, single-guide synergistic activation mediator. dCas9, deactivated or “dead” Cas9; n/a, not applicable; sgSAM, single-guide synergistic activation mediator. The commonly used JLat model, which simulates HIV-1 latency by using Jurkat T cells containing integrated but transcriptionally inactive proviruses, is employed by each laboratory group, allowing some direct comparison between the findings. Examination of the reactivation of transcription in JLat clones 9.2 and 10.6 provides convincing evidence that activation by a modified CRISPR/dCas9 system can be at least as effective as vorinostat. Limsirichai et al.3Limsirichai P Gaj T Schaffer DV CRISPR-mediated activation of latent HIV-1 expression.Mol Ther. 2016; 24: 499-507Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar additionally show evidence that this approach synergizes with vorinostat and prostratin treatment for increased activation. Saayman et al.2Saayman SM Lazar DC Scott TA Hart JR Takahashi M Burnett JC et al.Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex.Mol Ther. 2016; 24: 488-498Abstract Full Text Full Text PDF PubMed Scopus (94) Google Scholar and Ji et al.4Ji H Jiang Z Lu P Ma L Li C Pan H et al.Specific reactivation of latent HIV-1 by dCas9-SunTag-VP64-mediated guide RNA targeting the HIV-1 promoter.Mol Ther. 2016; 24: 508-521Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar both provide analysis of off-target effects and conclude that their approaches do not cause significant changes in gene expression or toxicity in the infected T cells. Examination of the three bodies of work reveals interesting differences as well. Each group chose a slightly different system for initial screening, often relying on alteration of a transiently transfected LTR reporter system. Saayman et al. describe the use of a LTR-mCherry-IRES-Tat (LChIT) latency reporter system.2Saayman SM Lazar DC Scott TA Hart JR Takahashi M Burnett JC et al.Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex.Mol Ther. 2016; 24: 488-498Abstract Full Text Full Text PDF PubMed Scopus (94) Google Scholar This construct expresses the mCherry reporter under control of the viral promoter and includes a Tat positive-feedback loop that mimics the reactivation seen with intact provirus. The authors use LChIT to construct a population of latency reporter cells, a technique that is of potential use in myriad latency studies. Ji et al. employ a SunTag system (Figure 1) that allows a single dCas9 protein to recruit over 20 copies of the VP64 activation domain for increased activity.4Ji H Jiang Z Lu P Ma L Li C Pan H et al.Specific reactivation of latent HIV-1 by dCas9-SunTag-VP64-mediated guide RNA targeting the HIV-1 promoter.Mol Ther. 2016; 24: 508-521Abstract Full Text Full Text PDF PubMed Scopus (60) Google Scholar Limsirichai et al. use the added approach of constructing a dCas9 fused to the histone acetyltransferase protein P300.3Limsirichai P Gaj T Schaffer DV CRISPR-mediated activation of latent HIV-1 expression.Mol Ther. 2016; 24: 499-507Abstract Full Text Full Text PDF PubMed Scopus (76) Google Scholar This approach is designed to acetylate the histones and open the chromatin to allow transcription to occur. Using dCas9-P300 they showed that targeting the nucleosome known as Nuc0 in the LTR can drive activation, supporting the intriguing conclusion that remodeling of this nucleosome may be an alternative approach to reversing latency. This is an interesting finding, as most work to date has focused on the nucleosome that is associated with the transcription start site (termed Nuc1) and not Nuc0, which is found upstream. These innovative studies offer good insight into the prospects of employing a CRISPR-mediated latency-reversing approach. The key benefits are the specificity, potency, and flexibility of these systems. However, further challenges remain. As a first step, lentiviral delivery systems for dCas9, such as those constructed by both Ji et al. and Limsirichai et al., need to be tested in a primary cell latency model or by a quantitative viral outgrowth assay on patient samples. Indeed, as with all gene therapy approaches, delivery is a consideration that must be addressed for any therapeutic application of the CRISPR/Cas9 system. The big question is whether activation induced by this system can induce useful cell killing. The specificity of CRISPR/Cas9 probably means that these approaches will not inhibit cytotoxic T-lymphocyte responses, as was observed with vorinostat, thus rendering these systems ideal candidates to be employed alongside immune-mediated methods of clearance." @default.
• W2296362429 created "2016-06-24" @default.
• W2296362429 creator A5021620199 @default.
• W2296362429 creator A5082730843 @default.
• W2296362429 date "2016-03-01" @default.
• W2296362429 modified "2023-10-06" @default.
• W2296362429 title "A CRISPR Approach for Reactivating Latent HIV-1" @default.
• W2296362429 cites W1964173449 @default.
• W2296362429 cites W1978917197 @default.
• W2296362429 cites W2049653440 @default.
• W2296362429 cites W2055142955 @default.
• W2296362429 cites W2060993125 @default.
• W2296362429 cites W2063622161 @default.
• W2296362429 cites W2076340146 @default.
• W2296362429 cites W2080166804 @default.
• W2296362429 cites W2081550246 @default.
• W2296362429 cites W2120014878 @default.
• W2296362429 cites W2126327824 @default.
• W2296362429 cites W2144549163 @default.
• W2296362429 cites W2152129968 @default.
• W2296362429 cites W2186907268 @default.
• W2296362429 cites W2205216869 @default.
• W2296362429 cites W2259873134 @default.
• W2296362429 doi "https://doi.org/10.1038/mt.2016.30" @default.
• W2296362429 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4786933" @default.
• W2296362429 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26952919" @default.
• W2296362429 hasPublicationYear "2016" @default.
• W2296362429 type Work @default.
• W2296362429 sameAs 2296362429 @default.
• W2296362429 citedByCount "3" @default.
• W2296362429 countsByYear W22963624292017 @default.
• W2296362429 countsByYear W22963624292018 @default.
• W2296362429 crossrefType "journal-article" @default.
• W2296362429 hasAuthorship W2296362429A5021620199 @default.
• W2296362429 hasAuthorship W2296362429A5082730843 @default.
• W2296362429 hasBestOaLocation W22963624291 @default.
• W2296362429 hasConcept C104317684 @default.
• W2296362429 hasConcept C159047783 @default.
• W2296362429 hasConcept C3013748606 @default.
• W2296362429 hasConcept C54355233 @default.
• W2296362429 hasConcept C70721500 @default.
• W2296362429 hasConcept C86803240 @default.
• W2296362429 hasConcept C98108389 @default.
• W2296362429 hasConceptScore W2296362429C104317684 @default.
• W2296362429 hasConceptScore W2296362429C159047783 @default.
• W2296362429 hasConceptScore W2296362429C3013748606 @default.
• W2296362429 hasConceptScore W2296362429C54355233 @default.
• W2296362429 hasConceptScore W2296362429C70721500 @default.
• W2296362429 hasConceptScore W2296362429C86803240 @default.
• W2296362429 hasConceptScore W2296362429C98108389 @default.
• W2296362429 hasIssue "3" @default.
• W2296362429 hasLocation W22963624291 @default.
• W2296362429 hasLocation W22963624292 @default.
• W2296362429 hasLocation W22963624293 @default.
• W2296362429 hasLocation W22963624294 @default.
• W2296362429 hasOpenAccess W2296362429 @default.
• W2296362429 hasPrimaryLocation W22963624291 @default.
• W2296362429 hasRelatedWork W1702322095 @default.
• W2296362429 hasRelatedWork W1865764402 @default.
• W2296362429 hasRelatedWork W1975114493 @default.
• W2296362429 hasRelatedWork W2118087741 @default.
• W2296362429 hasRelatedWork W2553969441 @default.
• W2296362429 hasRelatedWork W2936512310 @default.
• W2296362429 hasRelatedWork W3029386773 @default.
• W2296362429 hasRelatedWork W3092857740 @default.
• W2296362429 hasRelatedWork W3194505801 @default.
• W2296362429 hasRelatedWork W4213036952 @default.
• W2296362429 hasVolume "24" @default.
• W2296362429 isParatext "false" @default.
• W2296362429 isRetracted "false" @default.
• W2296362429 magId "2296362429" @default.
• W2296362429 workType "article" @default.